Search Results - "HAYNES, B. P"

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer by Anderson, H., Hills, M., Zabaglo, L., A'Hern, R., Leary, A.F., Haynes, B.P., Smith, I.E., Dowsett, M.

“…Surprisingly few data are published on the relevance of even commonly used biomarkers of response to aromatase inhibitors (AIs) in advanced breast cancer…”
Get full text

The pharmacology of letrozole by Haynes, B.P, Dowsett, M, Miller, W.R, Dixon, J.M, Bhatnagar, A.S

“…Recent clinical trials indicate that the third-generation aromatase inhibitors may be more effective than tamoxifen as first line endocrine therapy in ER+…”
Get full text

Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen by Dowsett, M., Haynes, B.P.

“…Third generation aromatase inhibitors have excellent specificity. Some reports indicate that letrozole may have a minor effect on cortisol synthesis but these…”
Get full text

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen by JOHNSTON, S. R. D, GUMBRELL, L. A, JONES, A, CANNEY, P, POWLES, T. J, HAYNES, B. P, NUTLEY, B, GRIMSHAW, R, JARMAN, M, HALBERT, G. W, BRAMPTON, M, HAVILAND, J, EVANS, T. R. J, DOWSETT, M, COOMBES, R. C, COLEMAN, R. E, SMITH, I. E, TWELVES, C. J, SOUKOP, M, REA, D. W, EARL, H. M, HOWELL, A

“…Idoxifene is a novel selective oestrogen receptor modulator (SERM) which had greater binding affinity for the oestrogen receptor (ER) and reduced agonist…”
Get full text

The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance by JOHNSTON, S. R. D, RIDDLER, S, HAYNES, B. P, A'HERN, R, SMITH, I. E, JARMAN, M, DOWSETT, M

“…The effect of idoxifene, a novel anti-oestrogen with less agonist activity than tamoxifen, was compared with that of tamoxifen on the growth of…”
Get full text

Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis by JOHNSTON, S. R. D, BOEDDINGHAUS, I. M, RIDDLER, S, HAYNES, B. P, HARDCASTLE, I. R, ROWLANDS, M, GRIMSHAW, R, JARMAN, M, DOWSETT, M

“…Idoxifene is a novel selective estrogen (E2) receptor (ER) modulator that is currently in clinical development for the treatment of breast cancer. Compared to…”
Get full text

Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration by Johnston, S R, Haynes, B P, Smith, I E, Jarman, M, Sacks, N P, Ebbs, S R, Dowsett, M

“…Reduced intra-tumoral drug concentrations have been investigated as a mechanism of tamoxifen resistance in 51 patients with locally recurrent breast cancer…”
Get more information

Idoxifene: report of a phase I study in patients with metastatic breast cancer by COOMBES, R. C, HAYNES, B. P, DOWSETT, M, QUIGLEY, M, ENGLISH, J, JUDSON, I. R, GRIGGS, L. J, POTTER, G. A, MCCAGUE, R, JARMAN, M

“…Idoxifene, a novel antiestrogen with reduced estrogenic activity when compared to tamoxifen, has been given to 20 women with metastatic breast cancer, 19 of…”
Get full text

Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer by JOHNSTON, S. R. D, HAYNES, B. P, SACKS, N. P. M, MCKINNA, J. A, GRIGGS, L. J, JARMAN, M, BAUM, M, SMITH, I. E, DOWSETT, M

“…While the presence of oestrogen receptors (ERs) in human breast cancer may determine the biological response to tamoxifen, the extent to which ER status…”
Get full text

Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors by Barrie, S E, Haynes, B P, Potter, G A, Chan, F C, Goddard, P M, Dowsett, M, Jarman, M

“…Two potent non-steroidal inhibitors (CB7645 and CB7661) of human cytochrome P450(17alpha) were tested for in vivo activity in WHT mice. There were no signs of…”
Get full text

The addition of neural networks to the inner feedback path in order to improve on the use of pre-trained feed forward estimators by Sanders, D.A., Haynes, B.P., Tewkesbury, G.E., Stott, I.J.

“…A learning control architecture which uses a multi-layer feed forward neural network with error back propagation is described. The architecture includes a feed…”
Get full text

Enantiomers of warfarin and vitamin K1 metabolism by Choonara, IA, Haynes, BP, Cholerton, S, Breckenridge, AM, Park, BK

“…The effect of the individual enantiomers of warfarin at steady state (1 mg daily) was investigated in five healthy volunteers. Both enantiomers produced a…”
Get full text

Pharmacokinetics and biodistribution of radiolabelled idoxifene: Prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy by Young, H., Carnochan, P., Trivedi, M., Potter, G.A., Eccles, S.A., Haynes, B.P., Jarman, M., Ott, R.J.

“…With a view to evaluating the role of PET imaging in the development of new anticancer drugs, we are investigating the novel antioestrogen…”
Get full text

The relationship between inhibition of vitamin K1 2,3‐epoxide reductase and reduction of clotting factor activity with warfarin by Choonara, IA, Malia, RG, Haynes, BP, Hay, CR, Cholerton, S, Breckenridge, AM, Preston, FE, Park, BK

“…1 The effect of low dose steady state warfarin (0.2 mg and 1 mg daily) on clotting factor activity and vitamin K1 metabolism was studied in seven healthy…”
Get full text

Stereoselective interaction between the R enantiomer of warfarin and cimetidine by Choonara, IA, Cholerton, S., Haynes, BP, Breckenridge, AM, Park, BK

“…The stereoselectivity of the pharmacokinetic interaction between warfarin and cimetidine was investigated in eight healthy volunteers. The warfarin enantiomers…”
Get full text

Plasma disposition of vitamin K1 in relation to anticoagulant poisoning by Park, BK, Scott, AK, Wilson, AC, Haynes, BP, Breckenridge, AM

“…The disposition of vitamin K1, after intravenous (10 mg) and oral doses (10 mg and 50 mg) was studied in six healthy male subjects. After intravenous…”
Get full text

Hepatic enzyme induction and vitamin K1 elimination in man by SCOTT, A. K, HAYNES, B. P, SCHINKEL, K. D, OHNHAUS, E. E, PARK, B. K

“…We have studied the effect of hepatic enzyme induction on vitamin K1 elimination in patients on long-term anticonvulsant therapy and in volunteers given…”
Get full text

Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer by HAYNES, B. P, JARMAN, M, DOWSETT, M, MEHTA, A, LOÊNNING, P. E, GRIGGS, L. J, JONES, A, POWLES, T, STEIN, R, COOMBES, R. C

“…The pyridylglutarimide 3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione (PyG) is a novel inhibitor of aromatase that was shown to cause effective suppression of…”
Get full text

Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4‐hydroxycoumarins by Park, BK, Choonara, IA, Haynes, BP, Breckenridge, AM, Malia, RG, Preston, FE

“…The case histories of two patients exposed to the novel anticoagulants brodifacoum and difenacoum are reported. Abnormal vitamin K1 metabolism, as indicated by…”
Get full text

Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients by Choonara, IA, Scott, AK, Haynes, BP, Cholerton, S., Breckenridge, AM, Park, BK

“…The disposition of, and pharmacological response to, a single intravenous dose of vitamin K1 (10 mg) was studied in eleven patients on daily warfarin therapy…”
Get full text